Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nada Nusrat

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
The Lancet. Oncology|February 14, 2022
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trialDean A Fennell, Amy King, Seid Mohammed, et al.
Nature Communications|July 21, 2025
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trialDean A Fennell, Kayleigh Hill, Min Zhang, et al.
Nature Communications|August 21, 2024
A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesotheliomaMin Zhang, Aleksandra Bzura, Essa Y Baitei, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
The Lancet. Oncology|February 14, 2022
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trialDean A Fennell, Amy King, Seid Mohammed, et al.
Nature Communications|July 21, 2025
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trialDean A Fennell, Kayleigh Hill, Min Zhang, et al.
Nature Communications|August 21, 2024
A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesotheliomaMin Zhang, Aleksandra Bzura, Essa Y Baitei, et al.
Pageof 1